For decades, the standard of care for obstructive sleep apnea (OSA) has been tethered to a rigid metric: the 90-day compliance threshold. Under current Medicare guidelines—a benchmark widely adopted by private insurers—patients must demonstrate that they use their Continuous Positive Airway Pressure (CPAP) device for at least four hours a night, for 70% of nights, within a 30-day period during the first 90 days of treatment. Failure to meet these specific parameters often results in the immediate cessation of insurance coverage, leaving patients without access to the equipment necessary to manage a chronic, potentially life-threatening condition.
However, a groundbreaking study presented at the American Thoracic Society (ATS) 2026 International Conference is now challenging the scientific validity of this policy. By analyzing the habits of over 132,000 patients, researchers have uncovered evidence that suggests the 90-day window is not only arbitrary but potentially harmful to long-term patient health.
The Foundation of the 90-Day Policy
To understand the significance of this new research, one must first understand the origin of the current policy. The Medicare coverage criteria for CPAP therapy were established to ensure that expensive medical equipment was being utilized effectively. The logic was simple: if a patient did not adapt to the device within the first three months, they were unlikely to become a long-term user. By tying reimbursement to usage, insurers aimed to minimize waste.
Yet, this "all-or-nothing" approach has long been criticized by sleep specialists who argue that CPAP therapy is notoriously difficult to initiate. Patients often report discomfort, mask leaks, or a general sense of claustrophobia during the initial weeks of treatment. Historically, clinical practice has viewed the first 90 days as a "trial period," but for many, it serves as a high-pressure deadline that can discourage those who simply need more time to adjust.
The ATS 2026 Findings: A Shift in Perspective
The research conducted at Kaiser Permanente Southern California offers a rare, large-scale look at how patients actually behave when the "threat" of coverage loss is removed. Because the Kaiser Permanente system provides CPAP therapy regardless of whether a patient meets the Medicare-defined early-use threshold, researchers were able to observe a diverse cohort of 132,000 OSA patients in a real-world setting.
The results were stark. The study found that 51% of patients failed to meet the traditional 90-day Medicare criteria. Under standard insurance models, more than half of these individuals would have had their machines reclaimed, effectively ending their therapy.
However, the longitudinal data told a different story. More than one-third of the patients who initially missed the Medicare threshold were still using their CPAP devices one year later. Even more telling, many of these "non-compliant" users were still utilizing their machines for at least two hours per night. While this falls below the four-hour mandate, clinical evidence suggests that even two hours of nightly usage can provide meaningful improvements in sleep quality and a reduction in OSA-related symptoms.
Chronology of the Research
The study, led by Dr. Dennis Hwang, a sleep and pulmonary physician at Kaiser Permanente Southern California, unfolded through a systematic review of electronic health records. The research team sought to bridge the gap between "early nonadherence" and "treatment failure."
- Baseline Observation: The researchers identified a massive cohort of 132,000 patients diagnosed with OSA within the Kaiser system.
- Comparative Analysis: The team tracked usage data against the standardized 90-day Medicare threshold, observing how many patients "passed" or "failed" the arbitrary benchmark.
- Long-Term Follow-Up: Researchers monitored the same cohort one year post-diagnosis to determine how many individuals continued to utilize their devices despite their initial performance.
- Clinical Outcome Assessment: The team cross-referenced usage data with reported patient symptoms to verify if those using the machines for less than four hours—but more than zero—were still seeing therapeutic benefits.
The timeline of the research highlights a critical discovery: the assumption that a slow start equals a permanent lack of engagement is mathematically and clinically flawed.
Supporting Data: By the Numbers
The data provided by the Kaiser Permanente study provides a compelling case for reform:
- The 51% Threshold: More than half of the study participants failed the 90-day Medicare criteria. If these patients were in a traditional insurance environment, their access to treatment would have been terminated.
- The 33% Persistence Rate: Of those who failed the early criteria, over 33% were still using their CPAP machines one year later. This represents a significant population of patients who would have been abandoned by the system but persisted in their own self-care.
- The "Two-Hour Benefit": The data indicates that usage of at least two hours per night is associated with symptom improvement. By mandating a four-hour floor, the current policy ignores the incremental benefits that patients receive during the "ramp-up" phase of treatment.
Official Responses and Clinical Implications
Dr. Dennis Hwang, the first author of the study, has been vocal about the implications of these findings. "Our findings suggest clinicians and policymakers should not rely solely on Medicare-defined adherence, given its reliance on early CPAP use and an arbitrary four-hour threshold, when making long-term treatment decisions," Dr. Hwang stated in an official release.
The clinical community is beginning to take note. The "arbitrary" nature of the four-hour rule has long been a point of contention in sleep medicine. For a patient suffering from severe apnea, four hours of usage is excellent; however, for a patient who is struggling with chronic insomnia or comorbid anxiety, achieving that four-hour mark in the first month is a significant barrier.
"Extending support and coverage beyond the first 90 days could help more patients achieve meaningful benefit," Dr. Hwang added. This shift in policy would require moving away from a "compliance" model—which treats patients as metrics to be managed—to a "support" model, which views the patient as an individual on a long-term wellness journey.
Implications for Healthcare Policy
The implications of this research are far-reaching. If insurers continue to adhere to the 90-day rule, they are essentially practicing a form of "administrative attrition," where the most vulnerable patients—those who take longer to adapt to therapy—are systematically cut off from care.
1. Reevaluating "Success"
The study proves that early nonadherence does not equate to treatment failure. Policy needs to shift from a rigid 90-day check-in to a more fluid, multi-month engagement strategy. If a patient is using their device for two hours, that is not a reason to stop coverage; it is an opportunity for clinical intervention, such as adjusting the mask, changing the pressure settings, or providing additional patient education.
2. Evidence-Based Coverage
Moving forward, the researchers plan to focus on identifying which patients are most likely to become long-term users. By utilizing predictive analytics rather than arbitrary thresholds, insurance companies could provide more resources to those who need them, rather than simply cutting them off.
3. The Human Cost
Beyond the financial metrics, there is a human cost to the current policy. OSA is linked to hypertension, cardiovascular disease, stroke, and type 2 diabetes. By removing CPAP access, the healthcare system may be saving money on equipment in the short term, only to pay significantly more for the emergency complications of untreated apnea in the long term.
The Path Forward
The path forward, according to the research team, lies in developing coverage policies that focus on patient outcomes rather than static usage thresholds. As the medical community digests these findings, there is a growing expectation that Medicare and private insurers will face increased pressure to modernize their criteria.
The era of the "90-day deadline" is likely nearing its end. As data-driven healthcare becomes the norm, policies that punish patients for the natural learning curve of medical treatment will become increasingly indefensible. For the millions of Americans struggling with obstructive sleep apnea, the findings from ATS 2026 represent a beacon of hope: the possibility of a healthcare system that values persistence and improvement over rigid, bureaucratic timelines.
The study serves as a powerful reminder that in medicine, the goal should be to keep patients on the path to health, even if they take a little longer to find their footing.
